Bausch Health Companies (NYSE:BHC) PT Lowered to $11.00 at Royal Bank of Canada

Bausch Health Companies (NYSE:BHC - Free Report) had its price target lowered by Royal Bank of Canada from $12.00 to $11.00 in a report issued on Tuesday, Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the stock.

Several other analysts also recently commented on the stock. StockNews.com raised shares of Bausch Health Companies from a hold rating to a buy rating in a research report on Wednesday, February 7th. Jefferies Financial Group dropped their price target on shares of Bausch Health Companies from $16.00 to $14.00 and set a buy rating on the stock in a report on Tuesday, February 20th.

Bausch Health Companies Stock Performance

Shares of Bausch Health Companies stock traded up $0.08 during trading on Tuesday, hitting $8.53. The company's stock had a trading volume of 4,025,446 shares, compared to its average volume of 2,802,447. The company has a fifty day simple moving average of $9.29 and a two-hundred day simple moving average of $8.16. The company has a market capitalization of $3.12 billion, a PE ratio of -5.27 and a beta of 0.85. Bausch Health Companies has a 52 week low of $5.57 and a 52 week high of $11.46.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.14. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The company had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period last year, the business earned $1.02 EPS. Bausch Health Companies's quarterly revenue was up 9.8% compared to the same quarter last year. As a group, analysts predict that Bausch Health Companies will post 3.95 EPS for the current year.

Institutional Trading of Bausch Health Companies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldentree Asset Management LP raised its holdings in Bausch Health Companies by 19.6% in the 3rd quarter. Goldentree Asset Management LP now owns 23,987,462 shares of the company's stock worth $197,177,000 after purchasing an additional 3,931,234 shares during the period. Nomura Holdings Inc. grew its stake in shares of Bausch Health Companies by 67.7% during the 3rd quarter. Nomura Holdings Inc. now owns 18,086,000 shares of the company's stock valued at $148,667,000 after acquiring an additional 7,303,015 shares during the period. Vanguard Group Inc. grew its stake in shares of Bausch Health Companies by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 11,599,131 shares of the company's stock valued at $93,025,000 after acquiring an additional 111,363 shares during the period. Hudson Bay Capital Management LP increased its holdings in Bausch Health Companies by 35.3% in the 3rd quarter. Hudson Bay Capital Management LP now owns 11,500,000 shares of the company's stock worth $94,530,000 after acquiring an additional 3,000,000 shares in the last quarter. Finally, Mizuho Markets Americas LLC purchased a new stake in Bausch Health Companies in the 3rd quarter worth approximately $57,540,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.